A recurrence risk of less than 0.5% at 6 years after surgery may provide a practical definition of “cure” in the setting of colon cancer.

Many trials that measure the efficacy and safety of antidepressants for MDD exclude one third of real-world patients with the ...

To drive true innovation in drug development, executives must not let excitement about the latest shiny object obscure ...

A study by the British Journal of Clinical Pharmacology (BJCP) has shown that by using artificial intelligence (AI), clinical trial assessors have been able to more than halve the time it takes to ...

Applying blockchain technology to clinical trials can help resolve one of the industry's biggest weaknesses: Poor data management. Learn how blockchain's immutability trait can become a trial ...

LINCOLN, Neb. — Nebraska over the past year handed the keys to its offense to Dana Holgorsen, renowned for the exploits of his passing game and a forefather of the Air Raid system. Control of the ...

When USC played its first game as a member of the Big Ten against Michigan last season, the Trojans got a not-so-friendly welcome to the "big boy" brand of football that teams from the conference ...

A model of Taiwanʼs Indigenous Defense Submarine at the Taipei Aerospace & Defense Technology Exhibition 2025. (Janes/Akhil Kadidal) Efforts to conclude sea trials of Taiwan's Indigenous Defense ...

Panini became the sole company with the rights to produce officially licensed NFL cards in 2009. A company from Italy that was well known for making soccer stickers, Panini totally revolutionized ...

A protein pill could help weight loss and improve sleep habits in obese adults, affirming the long-standing theory that sleep and metabolism are connected, according to a new study conducted at ...

The Arizona Diamondbacks will face three of the toughest possible teams on their schedule to close out the remainder of the 2025 regular season, and how they fare will determine whether they join the ...

The Jewish tradition of debate is at the center of a new chamber opera about two scholars clashing over a Yiddish dictionary in the aftermath of World War II. By Rob Tannenbaum Arguments, on topics ...